← Back to Search

DBV712 for Peanut Allergy (EPOPEX Trial)

Phase 3
Waitlist Available
Research Sponsored by DBV Technologies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

EPOPEX Trial Summary

This trial is for subjects who have already completed the EPITOPE study. It is an open-label follow-up, which means that both the subjects and the researchers know which treatment the subjects are receiving.

Who is the study for?
This trial is for young children who have completed the EPITOPE study and are dealing with peanut allergies. It's not open to those who've developed severe, unstable asthma or have widespread skin conditions like active eczema that would prevent applying Viaskin patches on clear skin areas.Check my eligibility
What is being tested?
The trial is testing the long-term efficacy and safety of a treatment called DBV712 at a dose of 250 mcg. This is an open-label follow-up study, meaning everyone knows they're getting the treatment and it's a continuation from an earlier phase.See study design
What are the potential side effects?
While specific side effects aren't listed here, treatments like DBV712 could potentially cause skin reactions where the patch is applied or allergic responses due to its nature as a therapy for peanut allergy.

EPOPEX Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects reaching an ED ≥1000 mg
Secondary outcome measures
Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)

EPOPEX Trial Design

1Treatment groups
Experimental Treatment
Group I: DBV712 250mcgExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

DBV TechnologiesLead Sponsor
16 Previous Clinical Trials
3,192 Total Patients Enrolled

Media Library

DBV712 250 mcg Clinical Trial Eligibility Overview. Trial Name: NCT03859700 — Phase 3
Peanut Allergy Research Study Groups: DBV712 250mcg
Peanut Allergy Clinical Trial 2023: DBV712 250 mcg Highlights & Side Effects. Trial Name: NCT03859700 — Phase 3
DBV712 250 mcg 2023 Treatment Timeline for Medical Study. Trial Name: NCT03859700 — Phase 3
~51 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top